Geron Highlights Oral Presentation At ASCO 2023 Meeting; To Show 'Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3'
Portfolio Pulse from Benzinga Newsdesk
Geron Corporation presented data at the ASCO 2023 Meeting, highlighting meaningful continuous transfusion independence observed in Imetelstat-treated lower risk MDS patients in the IMerge Phase 3 trial.
May 25, 2023 | 9:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Geron's presentation at the ASCO 2023 Meeting showed positive results for Imetelstat-treated lower risk MDS patients in the IMerge Phase 3 trial, potentially boosting investor confidence.
Geron's presentation at the ASCO 2023 Meeting highlighted positive results for Imetelstat-treated lower risk MDS patients in the IMerge Phase 3 trial. This news is directly related to Geron's product pipeline and may positively impact the company's stock price in the short term as it demonstrates progress in their clinical trials and potential future revenue streams.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100